Offer - Urjas Oil for just ₹ 1 X
Ivazine is a prescription medicine that is available as a Tablet. Primarily, it is used for the treatment of Heart Failure. Ivazine also has some secondary and off-label uses. These are listed below.
The correct dosage of Ivazine depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. For detailed information on this, read through the dosage section.
Common side effects of Ivazine include Blurred vision, Dizziness, Irregular heartbeat. Some other side effects of Ivazine have been listed ahead. These side effects of Ivazine are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Ivazine has a Severe effect for pregnant women and Unknown effect on lactating mothers. Warnings related to Ivazine's effects on the liver, heart and kidney, if any, have been listed below.
Ivazine can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Ivazine in conditions like Heart Failure, Bradycardia (Slow Heart Rate), Arrhythmia. Some other conditions that can be affected by Ivazine are listed in the contraindications section below.
Additionally, Ivazine may also adversely react with other medicines. Refer to the list below for further details.
You should also be aware that Ivazine is not safe while driving, and is not addiction.
Ivazine is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Geriatric |
|
Adult |
|
Is the use of Ivazine safe for pregnant women?
Ivazine can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Ivazine safe during breastfeeding?
Information about safety of Ivazine for women who are breastfeeding is not available since scientific research on this is yet to be done.
What is the effect of Ivazine on the Kidneys?
Ivazine rarely affects the kidneys.
What is the effect of Ivazine on the Liver?
Ivazine may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Ivazine on the Heart?
Ivazine has very mild side effects on the heart.
Ivazine should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Ivazine unless your doctor advises you to do so -
Is this Ivazine habit forming or addictive?
No, you will not get addicted to Ivazine.
Is it safe to drive or operate heavy machinery when consuming?
After taking Ivazine you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Ivazine is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Ivazine is not used to treat mental disorders.
Interaction between Food and Ivazine
Ivazine may take longer to act if you eat some foods while taking it. Follow your doctor's advice on this.
Interaction between Alcohol and Ivazine
No research has been done on this till date. Therefore, it is not known what the effect of taking Ivazine with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Corlanor® (ivabradine)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 554
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 720-721